RESUMO
Biologic drugs have transformed the standard of care for many diseases. However, many biologics induce the formation of anti-drug antibodies (ADAs), which can compromise their safety and efficacy. Preclinical studies demonstrate that biodegradable nanoparticles-encapsulating rapamycin (ImmTOR), but not free rapamycin, mitigate the immunogenicity of co-administered biologic drugs. Here we report the outcomes from two clinical trials for ImmTOR. In the first ascending dose, open-label study (NCT02464605), pegadricase, an immunogenic, pegylated uricase enzyme derived from Candida utilis, is assessed for safety and tolerability (primary endpoint) as well as activity and immunogenicity (secondary endpoint); in the second single ascending dose Phase 1b trial (NCT02648269) composed of both a double-blind and open-label parts, we evaluate the safety of ImmTOR (primary endpoint) and its ability to prevent the formation of anti-drug antibodies against pegadricase and enhance its pharmacodynamic activity (secondary endpoint) in patients with hyperuricemia. The combination of ImmTOR and pegadricase is well tolerated. ImmTOR inhibits the development of uricase-specific ADAs in a dose-dependent manner, thus enabling sustained enzyme activity and reduction in serum uric acid levels. ImmTOR may thus represent a feasible approach for preventing the formation of ADAs to a broad range of immunogenic biologic therapies.
Assuntos
Anticorpos/uso terapêutico , Hiperuricemia/tratamento farmacológico , Nanopartículas/química , Nanopartículas/uso terapêutico , Polietilenoglicóis/farmacologia , Urato Oxidase/uso terapêutico , Adulto , Idoso , Anticorpos/química , Terapia Biológica , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Compostos Orgânicos/química , Urato Oxidase/farmacologia , Ácido Úrico , Adulto JovemAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Compostos Bicíclicos Heterocíclicos com Pontes/efeitos adversos , Leucemia Mieloide Aguda/tratamento farmacológico , Sulfonamidas/efeitos adversos , Síndrome de Lise Tumoral/etiologia , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes/administração & dosagem , Citarabina/uso terapêutico , Decitabina/administração & dosagem , Feminino , Hidratação , Humanos , Hidroxiureia/uso terapêutico , Incidência , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/genética , Leucemia Mielomonocítica Aguda/complicações , Leucemia Mielomonocítica Aguda/tratamento farmacológico , Leucemia Mielomonocítica Aguda/genética , Leucocitose/tratamento farmacológico , Leucocitose/etiologia , Masculino , Pessoa de Meia-Idade , Proteínas de Ligação a Fosfato/uso terapêutico , Fósforo/sangue , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores , Estudos Retrospectivos , Sulfonamidas/administração & dosagem , Urato Oxidase/uso terapêutico , Ácido Úrico/sangueRESUMO
BACKGROUND: Tumor lysis syndrome is an oncologic emergency due to the release of tumor cell contents, leading to metabolic derangements. Rasburicase, a recombinant urate oxidase, catabolizes uric acid. At our institution, we administer a single 6-mg dose of rasburicase to patients who are at risk for tumor lysis syndrome. We aimed to assess the efficacy of single 6-mg dose of rasburicase and explore risk factors associated with rasburicase failure. METHODS: We report results in 92 adult patients who had a baseline uric acid greater than 7.5 mg/dL and received a single 6-mg dose of rasburicase for the management of tumor lysis syndrome. Responders were defined as those whose uric acid was less than or equal to 7.5 mg/dL within 24-36 h of rasburicase administration. The primary end point was response based on uric acid level. Secondary end points included response to rasburicase in association with lactate dehydrogenase, serum creatinine, calcium, phosphorus, blood pH, and oncologic diagnosis. RESULTS: Median age was 65 years and 70% were men. Most patients had leukemia (32%) or lymphoma (40%). Eighty-seven of 92 patients (95%), who received single 6-mg dose of rasburicase, achieved a uric acid less than 7.5 mg/dL within 24-36h of dosing. Body mass index was similar between responders and non-responders: 28.6 kg/m2 vs. 26.6 kg/m2, respectively, p = 0.6. Baseline lactate dehydrogenase levels were similar between the groups: 756 U/L vs. 892 U/L, respectively, p = 0.33. Blood pH values documented within 24 h of first dose of rasburicase were also similar between the two groups (n = 30; 7.33 vs. 7.34 respectively, p = 0.6). However, median baseline uric acid was lower in responders than non-responders: 12.3 mg/dL vs. 17.3 mg/dL, respectively, p = 0.012. Baseline serum creatinine and creatinine clearance were similar between responders and non-responders (2.2 mg/dL vs. 3.95 mg/dL; p = 0.12 and 29 mL/min vs. 16 mL/min; p = 0.11, respectively). CONCLUSIONS: Higher baseline uric acid levels were observed in patients who did not respond to the first rasburicase dose. In our study, uric acid levels normalized in 95% of patients after a single 6-mg dose of rasburicase indicating that a single 6-mg dose of rasburicase may be sufficient to manage tumor lysis syndrome, for most patients.
Assuntos
Supressores da Gota/uso terapêutico , Síndrome de Lise Tumoral/tratamento farmacológico , Urato Oxidase/uso terapêutico , Ácido Úrico/sangue , Centros Médicos Acadêmicos , Idoso , Antineoplásicos/efeitos adversos , Índice de Massa Corporal , Cálcio/sangue , Creatinina/sangue , Feminino , Supressores da Gota/administração & dosagem , Humanos , Concentração de Íons de Hidrogênio , Hiperuricemia/sangue , L-Lactato Desidrogenase/sangue , Leucemia/tratamento farmacológico , Linfoma/tratamento farmacológico , Masculino , Fósforo/sangue , Estudos Retrospectivos , Fatores de Risco , Síndrome de Lise Tumoral/etiologia , Síndrome de Lise Tumoral/prevenção & controle , Urato Oxidase/administração & dosagemRESUMO
The anti-inflammatory and immunomodulatory effects of nanoparticles in several chronic diseases have been extensively researched. The aim of this review is to examine how nanoparticles modulate the inflammatory pathways that characterize the most prevalent forms of microcrystal-induced arthritis, including gout, pseudogout, and BCP-induced arthritis. The nanoparticles of chitosan-coated calcium phosphate, uricase, aceclofenac, and gold have been investigated in crystal-inducedarthritis. The most important results of the studies outlined in this review show that nanoparticles can inhibit the expression and the release of some pro-inflammatory mediators and proteolytic enzymes, and the activity of different transcriptional factors in vitro, as well as decrease the uric acid levels in several studies of in vitro and in vivo models of gout, which show interesting results in terms of decreasing the amount of crystals and tissue damage, respectively. In view of their multiple beneficial effects, nanoparticles can be considered a valuable therapy that contributes to the pharmacological treatment in crystalinduced arthritis.
Assuntos
Fosfatos de Cálcio/uso terapêutico , Condrocalcinose/terapia , Artropatias por Cristais/terapia , Diclofenaco/análogos & derivados , Ouro/uso terapêutico , Nanopartículas/uso terapêutico , Urato Oxidase/uso terapêutico , Animais , Fosfatos de Cálcio/química , Quitosana/química , Diclofenaco/química , Diclofenaco/uso terapêutico , Modelos Animais de Doenças , Ouro/química , Humanos , Mediadores da Inflamação/metabolismo , Nanopartículas/química , Peptídeo Hidrolases/metabolismo , Urato Oxidase/química , Ácido Úrico/metabolismoRESUMO
An elevated level of serum uric acid-hyperuricemia, is strongly associated with the development of gout and chronic kidney disease (CKD) which is often accompanied by a significantly reduced glomerular filtration rate (GFR). In the present study, we investigated the extra-renal elimination of uric acid via the intestine in a healthy pig model and the effect of oral uricase therapy on plasma uric acid concentrations in pigs with induced hyperuricemia and CKD. The experiment was conducted on eleven, ten-week-old pigs (n = 11). The porcine model of CKD was developed by performing 9/10 nephrectomy surgery on eight pigs. A stable model of hyperuricemia was established in only five of the eight nephrectomized pigs by frequent injections of uric acid (UA) into the jugular vein. All pigs (three healthy pigs and five CKD pigs) were operated for implantation of jugular vein catheters and the three healthy pigs also had portal vein catheters inserted. Blood uric acid concentrations were measured spectrophotometrically, using the Uric Acid Assay Kit (BioAssay Systems, Hayward, USA). The piglets with CKD received orally administered uricase (treatment) and served as their own controls (without uricase supplementation). Oral uricase therapy significantly decreased plasma uric acid concentrations in pigs with CKD, whereas hyperuricemia was observed in the pigs whilst not being treated with uricase. Urinary uric acid excretion was similar during both the treatment and control periods during the first 8 h and 24 h after UA infusions in the CKD pigs. To demonstrate the elimination of UA via the intestine, the healthy pigs were infused with UA into the jugular vein. The blood collected from the jugular vein represents circulating UA concentrations and the blood collected from the portal vein represents the concentration of UA leaving the intestine. The final (after 2 h) concentration of UA was significantly lower in blood collected from the portal vein compared to that collected from the jugular vein (3.34 vs. 2.43 mg/dL, respectively, p = 0.024). The latter allows us to suggest that UA is eliminated from the blood via the gut tissue.
Assuntos
Hiperuricemia/sangue , Hiperuricemia/tratamento farmacológico , Urato Oxidase/administração & dosagem , Urato Oxidase/uso terapêutico , Ácido Úrico/sangue , Administração Oral , Animais , Modelos Animais de Doenças , Hiperuricemia/complicações , Hiperuricemia/urina , Mucosa Intestinal/metabolismo , Masculino , Nefrectomia , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/urina , Sus scrofa , Ácido Úrico/urinaRESUMO
Incidence and prevalence of gout have markedly increased over the last few decades in keeping with the rise in prevalence of obesity and metabolic syndrome. Until recently, management of gout in patients with associated metabolic syndrome and comorbid illnesses such as renal impairment was difficult because of limited treatment options. However, significant progress has been made in the last few years, with introduction of new treatments such as interleukin-1 antagonists for management of acute gout, and febuxostat and pegloticase for chronic gout. The association of gout with alcohol, dietary purines and fructose ingestion has been confirmed in large prospective studies, thus enabling the clinician to now provide evidence-based advice to patients. Recent efficacy and safety data favour lower over higher doses of colchicine, and oral corticosteroids over non-steroidal anti-inflammatory drugs for patients with acute gout. Local ice therapy might help to differentiate gout from other forms of inflammatory arthritis, and supplementation with vitamin C help to reduce risk of gout. Several other drugs with rational mechanisms of action are in the pipeline, and likely to be introduced over the next few years. A new era has thus begun in the field of gout.
Assuntos
Gota/terapia , Corticosteroides/uso terapêutico , Consumo de Bebidas Alcoólicas/efeitos adversos , Alopurinol , Anti-Inflamatórios não Esteroides/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Antirreumáticos/uso terapêutico , Ácido Ascórbico/uso terapêutico , Colchicina/uso terapêutico , Comorbidade , Crioterapia , Dieta , Relação Dose-Resposta a Droga , Febuxostat , Frutose/efeitos adversos , Gota/etiologia , Supressores da Gota/uso terapêutico , Humanos , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Polietilenoglicóis/uso terapêutico , Purinas/efeitos adversos , Receptores de Interleucina-1/antagonistas & inibidores , Proteínas Recombinantes de Fusão/uso terapêutico , Tiazóis/uso terapêutico , Urato Oxidase/uso terapêutico , Ácido Úrico/sangue , Uricosúricos/uso terapêutico , Vitaminas/uso terapêutico , Xantina Oxidase/antagonistas & inibidoresRESUMO
The tumor lysis syndrome (TLS) is a life-threatening complication caused by the massive release of nucleic acids, potassium and phosphate into the blood. This complication is the result of tumor cell lysis, which may occur due to treatment of drug sensitive and is characterized by rapid capacity of proliferation, that is often hematological origin. Moreover, the TLS can be observed before starting the treatment due to spontaneous tumor cell death, and frequently worsens when chemotherapy is initiated. TLS has high mortality, so that its prevention continues to be the most important therapeutic measure. In the intensive care unit (ICU), physicians should be aware of the clinical characteristics of TLS, which results in severe electrolyte metabolism disorders, especially hyperkalemia, hyperphosphatemia and hypocalcemia, and acute kidney injury which is a major cause of ICU mortality. An adequate strategy for the management of the TLS, combining hydration, urate oxidase, and an early admission to ICU can control this complication in most patients. The aim of this review is to provide diagnostic tools that allow to the ICU physician to recognize the population at high risk for developing the TLS, and outline a proper strategy for treating and preventing this serious complication.
Assuntos
Cuidados Críticos/métodos , Síndrome de Lise Tumoral/diagnóstico , Síndrome de Lise Tumoral/terapia , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/prevenção & controle , Injúria Renal Aguda/terapia , Alopurinol/uso terapêutico , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/prevenção & controle , Terapia por Quelação , Ensaios Clínicos como Assunto , Terapia Combinada , Hidratação , Humanos , Hiperpotassemia/tratamento farmacológico , Hiperpotassemia/etiologia , Hiperfosfatemia/tratamento farmacológico , Hiperfosfatemia/etiologia , Hipocalcemia/tratamento farmacológico , Hipocalcemia/etiologia , Incidência , Estudos Multicêntricos como Assunto , Prognóstico , Terapia de Substituição Renal , Fatores de Risco , Índice de Gravidade de Doença , Síndrome de Lise Tumoral/sangue , Síndrome de Lise Tumoral/epidemiologia , Síndrome de Lise Tumoral/prevenção & controle , Urato Oxidase/uso terapêuticoRESUMO
BACKGROUND: Rasburicase is indicated for the initial management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia. The labeled dose is 0.2 mg/kg/day administered intravenously over 30 minutes for up to 5 days. Our institutional adult guidelines recommend rasburicase 6 mg for uric acid levels >8 mg/dL in most adults with TLS, or 4-8 mg/dL in high-risk patients. Repeat dosing is indicated for uric acid levels >4 mg/dL determined ≥12 hours following the initial dose. OBJECTIVE: To determine the efficacy of a single dose of rasburicase 6 mg per institutional adult TLS guidelines to decrease uric acid levels to <4 mg/dL by day 3, as well as to determine the effect on serum creatinine and phosphorus concentrations. The secondary objectives were to evaluate the appropriateness of our institutional guidelines and identify TLS risk factors. METHODS: The study was approved by the University of Maryland Medical Center Institutional Review Board. A retrospective review of all adults between July 2008 and February 2009 who received at least one 6-mg dose of rasburicase, with redosing, if indicated, before day 3, was conducted. Subsequent TLS monitoring over 7 days after initial dosing was recorded. Patients were excluded if dosing did not adhere to institutional guidelines. RESULTS: We observed a decline in median uric acid levels from 9.2 mg/dL (interquartile range 8.1-10.4) on day 1 to between 1.8 (1.0-3.8) on day 3 and 3.8 mg/dL (2.1-4.4) on day 7 (p < 0.0001) with 2 patients requiring repeat dosing before day 3 (n = 34). The majority of the population was hyperuricemic (>8 mg/dL; 76%) or at high risk for TLS (85%). CONCLUSIONS: A 6-mg dose of rasburicase effectively decreased uric acid to <4 mg/dL by day 3, rarely requiring repeat dosing, in a high-risk population.
Assuntos
Supressores da Gota/administração & dosagem , Hiperuricemia/tratamento farmacológico , Neoplasias/tratamento farmacológico , Síndrome de Lise Tumoral/tratamento farmacológico , Urato Oxidase/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Creatinina/sangue , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Supressores da Gota/uso terapêutico , Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/tratamento farmacológico , Humanos , Hiperuricemia/sangue , Hiperuricemia/complicações , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Fósforo/sangue , Guias de Prática Clínica como Assunto , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Síndrome de Lise Tumoral/sangue , Síndrome de Lise Tumoral/complicações , Urato Oxidase/uso terapêutico , Ácido Úrico/sangueRESUMO
Savient Pharmaceuticals Inc (formerly Bio-Technology General Corp), under license from Duke University, is developing pegloticase, PEG conjugates of uricase (urate oxidase), for the potential treatment of gout. The in-life portion of the phase III trials have been completed.
Assuntos
Supressores da Gota/uso terapêutico , Gota/tratamento farmacológico , Polietilenoglicóis/uso terapêutico , Urato Oxidase/uso terapêutico , Animais , Preparações de Ação Retardada , Avaliação Pré-Clínica de Medicamentos , Supressores da Gota/administração & dosagem , Supressores da Gota/efeitos adversos , Supressores da Gota/farmacocinética , Humanos , Injeções Intravenosas , Estrutura Molecular , Patentes como Assunto , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/efeitos adversos , Polietilenoglicóis/farmacocinética , Proteínas Recombinantes/uso terapêutico , Relação Estrutura-Atividade , Resultado do Tratamento , Urato Oxidase/administração & dosagem , Urato Oxidase/efeitos adversos , Urato Oxidase/farmacocinéticaRESUMO
No disponible
Assuntos
Masculino , Feminino , Criança , Pré-Escolar , Humanos , Síndrome de Lise Tumoral/tratamento farmacológico , Urato Oxidase/uso terapêutico , Dose ÚnicaRESUMO
Tumor lysis syndrome is a life-threatening complication of chemotherapy for patients with leukemia and large tumors with a high proliferative index, such as Burkitt's lymphoma. The syndrome is characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. The standard of care for hyperuricemia consists of hydration with or without alkalinization and administration of allopurinol. When treated in this manner, patients often experience persistent hyperuricemia that lasts several days after the start of antineoplastic therapy; sometimes they develop uric acid nephropathy as a consequence. Rasburicase, a recombinant urate oxidase enzyme, quickly removes large amounts of uric acid from plasma. The drug is approved by the United States Food and Drug Administration for management of elevated plasma uric acid levels in pediatric patients with leukemia, lymphoma, or solid tumor malignancies who are receiving chemotherapy. We undertook a retrospective review of adult patients treated with a single dose of rasburicase 6 mg for hyperuricemia associated with malignancy. Ten patients received one 6-mg dose of rasburicase, and one patient received two 6-mg doses as an adjuvant therapy to normalize uric acid levels. In most of the patients, a single 6-mg dose of rasburicase was effective in correcting uric acid levels in the typical time between diagnosis and start of antineoplastic therapy.
Assuntos
Hiperuricemia/tratamento farmacológico , Hiperuricemia/etiologia , Neoplasias/complicações , Urato Oxidase/uso terapêutico , Idoso , Antineoplásicos/efeitos adversos , Creatinina/sangue , Feminino , Humanos , Hiperuricemia/induzido quimicamente , Leucemia/complicações , Linfoma/complicações , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Urato Oxidase/administração & dosagem , Ácido Úrico/sangueRESUMO
PURPOSE: The tumor lysis syndrome (TLS) is a set of complications that can arise from treatment of high burden, drug sensitive and rapidly proliferating neoplasm particularly of hematological origin. This syndrome can be observed before any treatment because of spontaneous tumoral cellular death, and is generally worsened when chemotherapy is initiated. CURRENT KNOWLEDGE AND KEY POINTS: Although TLS is primarily observed during therapy of acute leukemia, Burkitt's lymphomas and lymphoblastic lymphomas, it can also be observed in other hematological malignancies and during the treatment of rare solid tumors. Important progress has recently been made in the management of TLS. The use of urate oxydase can rapidly control TLS induced hyperuricemia, which help to prevent the risk of calcium phosphate crystal precipitation. FUTURE PROSPECTS AND PROJECTS: A global strategy for the management of SLT, combining adapted hydration, urate oxydase, and a close cooperation between intensive care units and hematology units can control this complication in most of the patients. The early management of TLS can, indeed, have an impact on the global therapy of these patients who need to be treated with high-dose anti-cancer agents with renal elimination.
Assuntos
Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/tratamento farmacológico , Síndrome de Lise Tumoral/terapia , Doença Aguda , Antineoplásicos/uso terapêutico , Hidratação , Humanos , Hiperuricemia/etiologia , Prognóstico , Fatores de Risco , Síndrome de Lise Tumoral/patologia , Urato Oxidase/uso terapêuticoAssuntos
Injúria Renal Aguda/etiologia , Injúria Renal Aguda/terapia , Síndrome de Lise Tumoral/complicações , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/prevenção & controle , Alopurinol/administração & dosagem , Diagnóstico Diferencial , Hidratação , Hemofiltração , Humanos , Hiperpotassemia/etiologia , Hiperpotassemia/terapia , Hiperuricemia/etiologia , Hiperuricemia/terapia , Fósforo/sangue , Diálise Renal , Síndrome de Lise Tumoral/diagnóstico , Urato Oxidase/uso terapêuticoRESUMO
PURPOSE: To improve the control of hyperuricemia in patients with leukemia or lymphoma, we tested a newly developed uricolytic agent, recombinant urate oxidase (SR29142; Rasburicase; Sanofi-Synthelabo, Inc, Paris, France), which catalyzes the oxidation of uric acid to allantoin, a highly water-soluble metabolite readily excreted by the kidneys. PATIENTS AND METHODS: We administered Rasburicase intravenously, at 0.15 or 0.20 mg/kg, for 5 to 7 consecutive days to 131 children, adolescents, and young adults with newly diagnosed leukemia or lymphoma, who either presented with abnormally high plasma uric acid concentrations or had large tumor cell burdens. Blood levels of uric acid, creatinine, phosphorus, and potassium were measured daily. The pharmacokinetics of Rasburicase, the urinary excretion rate of allantoin, and antibodies to Rasburicase were also studied. RESULTS: At either dosage, the recombinant enzyme produced a rapid and sharp decrease in plasma uric acid concentrations in all patients. The median level decreased by 4 hours after treatment, from 9.7 to 1 mg/dL (P =.0001), in the 65 patients who presented with hyperuricemia, and from 4.3 to 0.5 mg/dL (P =.0001) in the remaining 66 patients. Despite cytoreductive chemotherapy, plasma uric acid concentrations remained low throughout the treatment (daily median level, 0.5 mg/dL). The urinary excretion rate of allantoin increased during Rasburicase treatment, peaking on day 3. Serum phosphorus concentrations did not change significantly during the first 3 days of treatment, decreased significantly by day 4 in patients presenting with hyperuricemia (P =.0003), and fell within the normal range in all patients by 48 hours after treatment. Serum creatinine levels decreased significantly after 1 day of treatment in patients with or without hyperuricemia at diagnosis (P =.0003 and P =.02, respectively) and returned to normal range in all patients by day 6 of treatment. Toxicity was negligible, and none of the patients required dialysis. The mean plasma half-lives of the agent were 16.0 +/- 6.3 (SD) hours and 21.1 +/- 12.0 hours, respectively, in patients treated at dosages of 0.15 or 0.20 mg/kg. Seventeen of the 121 assessable patients developed antibodies to the enzyme. CONCLUSION: Rasburicase is safe and highly effective for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma.